Rucaparib Camsylate

Form: Oral tablets

Strength: 200 mg, 250 mg, 300 mg

Reference Brands: Rubraca® (EU & US)

Category: Oncology Cancer Care

Rucaparib Camsylate is an innovative PARP inhibitor used in the treatment of ovarian, fallopian tube, and peritoneal cancers. This targeted therapy is especially effective in cancers with BRCA mutations, as it disrupts DNA repair mechanisms in cancer cells, leading to their destruction. Available under the brand name Rubraca®, it is offered in 200 mg, 250 mg, and 300 mg oral tablet strengths. Manufactured under GMP-certified conditions, Rucaparib is a trusted solution in oncology care. Ideal for US and EU pharmaceutical distributors and wholesalers, it provides an advanced treatment option in precision medicine for cancer patients.